CASI Pharmaceuticals Incorporation Portions purchases by the Bank of New York Mellon Corporation

CASI pharma

Bank of New York Mellon Corp grew its holdings in CASI Pharmaceuticals Inc (NASDAQ:CASI) by 12.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 172,947 shares of the biotechnology company’s stock after purchasing an additional 19,781 shares during the quarter. Bank of New York Mellon Corp owned about 0.18% of CASI Pharmaceuticals worth $695,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of CASI. Meeder Asset Management Inc. grew its position in shares of CASI Pharmaceuticals by 63.4% in the fourth quarter. Meeder Asset Management Inc. now owns 9,579 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 3,716 shares during the last quarter. Rhumbline Advisers grew its position in shares of CASI Pharmaceuticals by 50.3% in the fourth quarter. Rhumbline Advisers now owns 64,395 shares of the biotechnology company’s stock valued at $259,000 after purchasing an additional 21,563 shares during the last quarter.

Wells Fargo & Company MN grew its position in shares of CASI Pharmaceuticals by 52.2% in the third quarter. Wells Fargo & Company MN now owns 62,606 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 21,468 shares during the last quarter. Teachers Advisors LLC grew its position in shares of CASI Pharmaceuticals by 12.4% in the third quarter. Teachers Advisors LLC now owns 107,422 shares of the biotechnology company’s stock valued at $502,000 after purchasing an additional 11,816 shares during the last quarter. Finally, Alps Advisors Inc. grew its position in shares of CASI Pharmaceuticals by 43.7% in the fourth quarter. Alps Advisors Inc. now owns 220,215 shares of the biotechnology company’s stock valued at $885,000 after purchasing an additional 66,981 shares during the last quarter. 11.93% of the stock is currently owned by institutional investors.

Separately, Bidask Club downgraded CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, January 11th.

CASI stock opened at $3.26 on Friday. CASI Pharmaceuticals Inc. has a twelve month low of $2.73 and a twelve month high of $8.89. The stock has a market cap of $304.39 million, a P/E ratio of -10.03 and a beta of 1.19.

CASI Pharmaceuticals is the last released its earnings results on Friday, March 29th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Analysts anticipate that CASI Pharmaceuticals Inc. will post -0.23 EPS for the current year.